Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 11/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884939 | 0.82 | OPRL1 (0.36) | OPRL1KCNH2HDAC1HDAC6MAOA | |
| SCHEMBL2881576 | 0.81 | OPRL1 (0.36) | OPRL1KCNH2HDAC1HDAC6 | |
| SCHEMBL2883839 | 0.75 | OPRL1 (0.59) | OPRL1KCNH2 | |
| SCHEMBL2884942 | 0.71 | ADORA2A (0.30) | ADORA2A | |
| SCHEMBL26120988 | 0.70 | DRD2 (0.41) | OPRL1KCNH2 | |
| SCHEMBL14893181 | 0.70 | OPRL1 (0.40) | OPRL1KCNH2HDAC1HDAC6 | |
| SCHEMBL2877878 | 0.68 | OPRL1 (0.39) | OPRL1KCNH2 | |
| SCHEMBL2883261 | 0.68 | OPRL1 (0.39) | OPRL1KCNH2 | |
| SCHEMBL14012294 | 0.67 | TRPV1 (0.52) | HDAC1HDAC6TRPV1ADORA2A | |
| SCHEMBL31678106 | 0.67 | TRPV1 (0.52) | HDAC1HDAC6TRPV1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | OPRL1 1/4885KCNH2 969/4885HDAC1 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.